<DOC>
	<DOCNO>NCT00141219</DOCNO>
	<brief_summary>To evaluate efficacy pregabalin , use flexible , optimize dose schedule dose adjustment base Daily Pain Rating Scale ( DPRS ) , compare placebo subject peripheral neuropathic pain .</brief_summary>
	<brief_title>Pregabalin Peripheral Neuropathic Pain Study</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Diagnosis peripheral neuropathic pain syndrome , include diabetic peripheral neuropathy ( DPN ) , postherpetic neuralgia ( PHN ) , posttraumatic neuropathic pain ( include postsurgical ) , confirm qualified pain specialist . Subjects must complete least 4 daily pain diary 7 day prior Visit 2 average pain score â‰¥4 7 day prior Visit 2 ( randomization ) . Neurologic disorder unrelated DPN , PHN , posttraumatic neuropathic pain ( include postsurgical ) , may confuse confound assessment neuropathic pain . Presence severe pain associated condition DPN , PHN , posttraumatic neuropathic pain ( include postsurgical ) may confound assessment self evaluation pain due DPN , PHN , posttraumatic neuropathic pain ( include postsurgical ) . Creatinine clearance &lt; 30 mL/min ( estimate serum creatinine , body weight , age , sex use Cockcroft Gault equation Appendix E ) . Maximum dose subject creatinine clearance 30 60 mL/min 300 mg/day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>